Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial

R K Simmons, S J Sharp, A Sandbæk, K Borch-Johnsen, M J Davies, K Khunti, T Lauritzen, G E H M Rutten, M van den Donk, N J Wareham, S J Griffin, R K Simmons, S J Sharp, A Sandbæk, K Borch-Johnsen, M J Davies, K Khunti, T Lauritzen, G E H M Rutten, M van den Donk, N J Wareham, S J Griffin

Abstract

Aims: To describe the total cardiovascular burden (cardiovascular morbidity or mortality, revascularization or non-traumatic amputation) in individuals with screen-detected diabetes in the ADDITION-Europe trial and to quantify the impact of the intervention on multiple cardiovascular events over 5 years.

Methods: In a pragmatic, cluster-randomized, parallel-group trial in four centres (Denmark; Cambridge, UK; the Netherlands; and Leicester, UK), 343 general practices were randomized to screening plus routine care (n = 1379 patients), or screening and promotion of target-driven, intensive treatment of multiple risk factors (n = 1678). We estimated the effect of the intervention on multiple cardiovascular events after diagnosis of diabetes using the Wei, Lin and Weissfeld method.

Results: Over 5.3 years, 167 individuals had exactly one cardiovascular event, 53 exactly two events, and 18 three or more events. The incidence rates (95% CI) of first events and any event per 1000 person-years were 14.6 (12.8-16.6) and 20.4 (18.2-22.6), respectively. There were non-significant reductions in the risk of a first (hazard ratio 0.83, 95% CI 0.65-1.05) and second primary endpoint (hazard ratio 0.70, 95% CI 0.43-1.12). The overall average hazard ratio for any event was 0.77 (95% CI 0.58-1.02).

Conclusions: Early intensive multifactorial treatment was not associated with a significant reduction in total cardiovascular burden at 5 years. Focusing on first events in cardiovascular disease prevention trials underestimates the total cardiovascular burden to patients and the health service.

Trial registration: ClinicalTrials.gov NCT00237549.

© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK.

Figures

FIGURE 1
FIGURE 1
The effect of the intervention on the hazard of experiencing one, two, three, four and any event. Each intervention effect is presented as a hazard ratio within each country and combined across countries using fixed-effects meta-analysis. Only Denmark had sufficient numbers of individuals to estimate an intervention effect for three and four events. All I2-values for each comparison were 0%.

References

    1. UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Br Med J (Clin Res Ed. 1998;317:703–713.
    1. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care. 1997;20:614–620.
    1. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772.
    1. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591.
    1. Simmons RK, Echouffo-Tcheugui JB, Griffin SJ. Screening for type 2 diabetes: an update of the evidence. Diabetes Obes Metabol. 2010;12:838–844.
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
    1. National Screening Committee. Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management. University of Leicester: National Screening Committee; 2008.
    1. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011;378:156–167.
    1. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008;29:2473–2479.
    1. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009;54:2358–2362.
    1. LaRosa JC, Deedwania PC, Shepherd J, Wenger NK, Greten H, DeMicco DA, et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial) Am J Cardiol. 105:283–287.
    1. Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol. 2009;54:2353–2357.
    1. Nissen SE. Cardiovascular outcomes in randomized trials: should time to first event for ‘hard’ endpoints remain the standard approach? J Am Coll Cardiol. 2009;54:2363–2365.
    1. Scholte op Reimer WJM, Gitt AK, Boersma E, Simoons ML, editors. Cardiovascular Diseases in Europe. Sophia Antipolis, France: European Society of Cardiology; 2004.
    1. Chen BE, Cook RJ. Tests for multivariate recurrent events in the presence of a terminal event. Biostatistics. 2004;5:129–143.
    1. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord. 2000;24:S6–11.
    1. Echouffo-Tcheugui JB, Simmons RK, Williams KM, Barling RS, Prevost AT, Kinmonth AL, et al. The ADDITION-Cambridge trial protocol: a cluster-randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. BMC Public Health. 2009;9:136.
    1. Webb DR, Khunti K, Srinivasan B, Gray LJ, Taub N, Campbell S, et al. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials. 2010;11:16.
    1. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract. 2009;59:43–48.
    1. Sandbaek A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K, et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia. 2008;51:1127–1134.
    1. Sargeant LA, Simmons RK, Barling RS, Butler R, Williams KM, Prevost AT, et al. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabet Med. 2010;27:995–1003.
    1. van den Donk M, Sandbaek A, Borch-Johnsen K, Lauritzen T, Simmons RK, Wareham NJ, et al. Screening for Type 2 diabetes. Lessons from the ADDITION-Europe study. Diabet Med. 2011;28:1416–1424.
    1. WHO. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva: World Health Organization; 1999.
    1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393.
    1. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–259.
    1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853.
    1. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016.
    1. Royal College of General Practitioners in Denmark. Type 2 Diabetes in General Practice – Diagnosis and Treatment. Copenhagen, Denmark: Royal College of General Practitioners in Denmark; 1999.
    1. McIntosh A, Hutchison A, Home PD, Brown F, Bruce A, Damerell A, et al. Clinical Guidelines and Evidence Review for Type 2 Diabetes: Management of Blood Glucose. Sheffield: ScHARR, University of Sheffield; 2001.
    1. Rutten GEHM, Verhoeven S, Heine RJ, De Grauw WJC, Cromme PVM, Reenders K. Dutch College of General Practitioners. Practice guideline diabetes mellitus type 2. Huisarts Wetensch. 1999;42:67–84.
    1. NICE. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care. London: National Institute for Health and Clinical Excellence; 2008.
    1. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989;84:1065–1073.
    1. Metcalfe C, Thompson SG. Wei, Lin and Weissfeld’s marginal analysis of multivariate failure time data: should it be applied to a recurrent events outcome? Stat Methods Med Res. 2007;16:103–122.
    1. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, et al. Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. Diabetes Care. 2008;31:2154–2159.
    1. Doran T, Fullwood C, Gravelle H, Reeves D, Kontopantelis E, Hiroeh U, et al. Pay-for-performance programs in family practices in the UK. N Engl J Med. 2006;355:375–384.
    1. Royal College of General Practitioners in Denmark. Type 2 Diabetes in General Practice – An Evidence-Based Guideline. Copenhagen, Denmark: Royal College of General Practitioners in Denmark; 2004.
    1. Rutten GEHM, de Grauw WJC, Nijpels G, Goudswaard AN, Uitewaal PJM, Van der Does FEE, et al. Dutch guidelines on Type 2 diabetes mellitus. Dutch College of General Practitioners. Huisarts Wetensch. 2006;49:137–152.
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med J. 2008;359:1577–1589.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe